News We’re Watching – Medicare Covers Dexcom CGM; New Mpox EUA; $106M Patent Verdict Against Medtronic
Executive Summary
Medicare announced coverage for the Dexcom G7 continuous glucose monitor, as well as a breast cancer indication for Natera Inc.’s Signatera; the FDA authorized a new monkeypox test; the FDA issued a warning letter to a Texas masks firm; and a new report says NIST labs are failing behind.
You may also be interested in...
Dexcom Doubles Down On Jonas Branding To Hail G7 Launch
Dexcom is commemorating the US launch of its G7 continuous glucose monitor with an expensive ad spot during the Super Bowl.
Dexcom Touts G7 As ‘The Most Accurate CGM’ As It Prepares For US Launch
The US FDA has granted authorization to Dexcom to market its G7 continuous glucose monitor, which the company will launch in the next couple of months.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.